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Summary 
The RAS/MAPK-signalling pathway is frequently deregulated in non-small cell lung cancer 
(NSCLC), often through KRAS activating mutations1-3. A single endogenous mutant Kras allele 
is sufficient to promote lung tumour formation in mice but malignant progression requires 
additional genetic alterations4-7. We recently showed that advanced lung tumours from 
KrasG12D/+;p53-null mice frequently exhibit KrasG12D allelic enrichment (KrasG12D/Kraswild-type>1)7, 
implying that mutant Kras copy gains are positively selected during progression. Through a 
comprehensive analysis of mutant Kras homozygous and heterozygous MEFs and lung cancer 
cells we now show that these genotypes are phenotypically distinct. In particular, KrasG12D/G12D 
cells exhibit a glycolytic switch coupled to increased channelling of glucose-derived metabolites 
into the TCA cycle and glutathione biosynthesis, resulting in enhanced glutathione-mediated 
detoxification. This metabolic rewiring is recapitulated in mutant KRAS homozygous NSCLC 
cells and in vivo, in spontaneous advanced murine lung tumours (which display a high 
frequency of KrasG12D copy gain), but not in the corresponding early tumours (KrasG12D 
heterozygous). Finally, we demonstrate that mutant Kras copy gain creates unique metabolic 
dependences that can be exploited to selectively target these aggressive mutant Kras tumours. 
Our data demonstrate that mutant Kras lung tumours are not a single disease but rather a 
heterogeneous group comprised of two classes of tumours with distinct metabolic profiles, 
prognosis and therapeutic susceptibility, which can be discriminated based on their relative 
mutant allelic content. We also provide the first in vivo evidence of metabolic rewiring during 
lung cancer malignant progression.  
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The Ras pathway8 is frequently upregulated during the malignant progression of mutant Kras 
tumours5,9, indicating that this transition requires further increased Ras activity. But how this 
activity may contribute to malignant progression remains unclear. We recently identified mutant 
Kras (Krasmut) copy gains in high-grade murine lung tumours7 and mutant-specific gains have 
also been reported in NSCLC2,10. We thus hypothesized that the gain of a second Krasmut copy 
affords additional oncogenic phenotypes to Kras heterozygous cells. To identify such potential 
gain-of-function phenotypes, we compared the acute impact of KrasG12D-endogenous allele11 
activation in heterozygous and homozygous KrasG12D mouse embryonic fibroblasts (MEFs). 
MEFs were generated on a p53-null background12 (Extended Data Fig. 1a) to recapitulate the 
tumour genotype where KrasG12D copy gains were identified7 but for simplicity, hereafter they will 
be termed Kraswild-type/wild-type (WT/WT), KrasG12D/WT and KrasG12D/G12D.  
As reported11, KrasG12D/WT cells showed a proliferative advantage relative to KrasWT/WT MEFs. 
Surprisingly, KrasG12D/WT and KrasG12D/G12D cells grew similarly at early passages (P1-P5) (Fig. 
1a,b), indicating that proliferation is not directly affected by Krasmut copy gain. A growth 
advantage of KrasG12D/G12D cells was nevertheless observed after P6. To identify both immediate 
and proliferation-independent KrasG12D copy gain-dependent effects subsequent analyses were 
restricted to early passages. While KRAS amplifications are typically associated with increased 
expression2,10, KrasG12D/WT and KrasG12D/G12D Ras protein levels were comparable and only 
slightly increased relative to KrasWT/WT MEFs. Nevertheless, KrasG12D/G12D MEFs exhibited a ~2-
fold increase in activated Ras relative to KrasG12D/WT cells (Fig. 1c), indicating that mutant copy 
gain may have functional implications. In agreement, microarray analysis identified 1666 genes 
differentially regulated (>1.3 fold) between KrasG12D/G12D and KrasG12D/WT MEFs, with glycolysis 
being the most significantly altered pathway (Fig. 1d and Extended Data Fig.1b). 
Mutant Kras activity enhances glucose uptake and rewires glucose metabolism into the 
hexosamine biosynthesis and pentose phosphate pathways in pancreatic ductal 
adenocarcinoma13. However, its metabolic impact on other cancer types and more importantly, 
that of Krasmut copy gain is unclear.	  KrasG12D/WT and KrasWT/WT MEFs showed similar glycolytic 
gene expression profiles with the exception of Slc2a1 (Glut1) and Slc2a3 (Glut3, data not 
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shown).	   In contrast, in KrasG12D/G12D MEFs glycolytic gene expression was significantly 
upregulated and mirrored by increased glucose uptake, lactate secretion and glycolytic capacity 
(Fig. 1e,f and Extended Data Fig. 1c,d). Thus, we show that KrasG12D copy gain induces a 
glycolytic switch while a Kras mutation per se is not sufficient to upregulate glycolysis. Notably, 
analysis of murine lung tumour cell lines with distinct Kras G12D/WT allelic content revealed a 
direct correlation between increased KrasG12D copy number (KrasG12D/total Kras) and enhanced 
GTPase activity and glycolysis (ECAR), consistent with a “Krasmut-dosage” effect. Glycolytic 
gene expression, glucose uptake and lactate secretion were also significantly enhanced in 
KrasG12D/G12D relative to heterozygous tumour cells (Fig. 1g and Extended Data Fig. 1e-g). 
Importantly, Krasmut homozygosity is highly prevalent (48.6%) within mutant KRAS NSCLC cell 
lines (COSMIC), underscoring its relevance and enabling the validation of our findings in a 
clinically relevant NSCLC model. Reassuringly, the distinct glycolytic phenotypes of KRASmut 
heterozygous and homozygous cells were confirmed in NSCLC cells (Fig. 1h and Extended 
Data Table 1), demonstrating that glycolysis upregulation is a Krasmut copy gain-associated gain-
of-function.	  
Enhanced glycolysis is a well-recognised cancer phenotype typically associated with increased 
growth demands, and/or compensatory adaptation to mitochondrial defects14,15. Yet, early 
passage KrasG12D/G12D MEFs displayed a glycolytic switch relative to KrasG12D/WT cells despite 
exhibiting comparable proliferative rates, cell volume, diameter, protein and RNA content (Fig. 
1a,b and Extended Data Fig. 2a-d). Furthermore, mitochondrial morphology and function were 
similar across genotypes (Extended Data Fig. 2e-h), despite a KrasG12D-associated decrease in 
membrane potential, as reported under overexpression conditions15,16.	  We then hypothesised 
that this glycolytic switch reflected alternative glucose utilization by KrasG12D/G12D cells. 
Metabolomics analysis confirmed the enhanced glycolytic phenotype of KrasG12D/G12D cells and 
unexpectedly, uncovered a significant increase in glucose-derived TCA cycle metabolites in 
Krasmut homozygous MEFs and (murine and human) lung tumour cells (Fig. 2 and Extended 
Data Fig. 3,4), confirming their intact mitochondrial function. More importantly, these data 
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identified a Krasmut copy gain-specific metabolic rewiring and uncovered a (TCA-coupled) 
glucose metabolism signature not previously associated with mutant Kras activity. 	  
Despite their differential glucose utilisation, KrasG12D/WT and KrasG12D/G12D MEFs had similar 
oxidative phosphorylation levels (Extended Data Fig.2e), hinting to additional TCA cycle 
differences. Since Krasmut cells were reported to preferentially utilise glutamine, rather than 
glucose, to fuel the TCA cycle17,18 glutamine metabolism was assessed. Glutamine-derived TCA 
cycle metabolites were increased in KrasG12D/WT cells and glutamine-derived oxygen 
consumption was also enhanced in KrasG12D/WT, but not KrasG12D/G12D, relative to KrasWT/WT MEFs 
(Extended Data Fig.5a-j). However, unlike the genotype-specific glucose metabolism 
signatures, differential glutamine utilisation could not be consistently recapitulated in tumour 
cells (data not shown), possibly reflecting their proliferative and oxygen consumption rate (OCR) 
heterogeneity. Thus, KrasG12D/WT-specific glutamine metabolism rewiring is either MEF-specific 
or masked by other mutations in cancer cells.  
Enhanced pyruvate dehydrogenase (Pdh) activity19 could explain the glucose metabolism 
reprogramming exhibited by homozygous cells. But since KrasG12D/G12D and KrasG12D/WT MEFs 
showed comparable Pdhe1a expression and Pdh activity (Fig. 3a) we speculated that instead, 
genotype-specific metabolic requirements drive this metabolic switch. Surprisingly, our 
metabolomics data showed that glutathione (GSH) and its precursors serine, glycine and 
glutamate were strikingly enriched with glucose-derived carbons in Krasmut homozygous cells 
(Figure 2 and Extended Data Fig. 3c-e,i,4d-f,h,l,m), implying that Krasmut copy gain rewired 
glucose metabolism towards glutathione biosynthesis. Even glutamine was more efficiently 
metabolised towards GSH biosynthesis in KrasG12D/G12D MEFs (Extended Data Fig. 5g,k). We 
therefore assessed the impact of KrasG12D-gain on redox management. Consistent with previous 
reports18,20, KrasG12D/WT MEFs showed decreased ROS levels and increased NADPH/NADP+ 
ratio relative to KrasWT/WT. Nevertheless, KrasG12D/G12D MEFs exhibited a more striking 
antioxidant signature, marked by significantly increased NADPH and GSH synthesis, 
NADPH/NADP+ and GSH/GSSG ratios and conversely, lower ROS levels and increased 
resistance to ROS-inducing agents (H2O2) (Fig. 3b-e and Extended Fig. 6a). Mutant Kras was 
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previously associated with enhanced expression and activity of the antioxidant programme 
regulator Nrf221 in KrasG12D/WT;p53+/+ MEFs20, potentially explaining the increased redox potential 
of our KrasG12D/G12D;p53-/- MEFs. Despite exhibiting comparable Nrf2 expression to heterozygous 
(Fig. 3f), KrasG12D/G12D MEFs showed upregulation of Nrf2-regulated GSH utilisation genes21, 
indicating that increased Nrf2-mediated detoxification may contribute to their metabolic rewiring.  
The metabolic heterogeneity of Krasmut cells can potentially limit the efficacy of generalised 
targeting approaches22, prompting us to explore potential Krasmut copy number-dependent 
susceptibilities. Unlike heterozygotes, KrasG12D/G12D MEFs were very sensitive to low glucose 
levels and the glucose analogue 2-Deoxy-D-glucose (2DG), which induced a dramatic apoptotic 
response (Fig. 3g,h). In turn, KrasG12D/WT MEFs showed higher sensitivity to low glutamine. 
Confirming a reliance on glucose for efficient ROS management, KrasG12D/G12D cells (but not 
KrasWT/WT or KrasG12D/WT) showed increased ROS levels upon 2DG treatment, while N-acetyl-L-
cysteine (NAC, GSH precursor) partially rescued their 2DG-induced apoptosis (Extended Data 
Fig. 6b,c). Moreover, combined 2DG and L-buthionine-S,R-sulfoximine (BSO, GSH biosynthesis 
inhibitor23) treatment induced drastic, KrasG12D/G12D-specific apoptosis and reduction in 
GSH/GSSG ratio (Fig. 3h and Extended Data Fig. 6d). Likewise, murine and human Krasmut 
homozygous lung cancer cells exhibited increased GSH levels, GSH/GSSG ratio and enhanced 
sensitivity to low glucose, 2DG and 2DG/BSO, relative to heterozygotes (Fig. 3i,j and Extended 
Data Fig. 6e-g), revealing a mutant Kras copy gain-specific susceptibility to glucose and 
glutathione depletion in lung cancer cells. 
Finally, we defined the metabolic impact of KrasG12D copy gain in vivo using the spontaneous 
KrasG12D/+;p53-/- lung tumours where these gains were originally reported7. These tumours 
progress over time from low- to high-grade, with KrasG12D gains being associated with the latter, 
prompting us to compare glucose flux in early (mostly low-grade) and late (typically advanced) 
tumours. Control or tumour-bearing mice were infused with 13C-glucose and normal lung or 
individual tumours isolated for LC-MS analysis and biopsied for Kras locus assessment. Early 
tumours and control lung showed similar KrasG12D allelic content (mean 46.7 and 46.2% 
respectively; Fig. 4a), demonstrating that early lesions are predominantly heterozygous. In 
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contrast, late tumours showed increased KrasG12D allelic prevalence (mean >50%), confirming 
mutant enrichment in advanced disease7. Importantly, and consistent with our in vitro data, late 
tumours exhibited an increase in glucose-derived TCA cycle metabolites, as well as serine, 
glycine and GSH (Fig. 4b and Extended Data Fig. 7). Notably, by showing that early and late 
tumours have distinct metabolic profiles we provide, to our knowledge, the first evidence of in 
vivo metabolic reprogramming during lung cancer malignant progression. 
KrasG12D copy gain also drove increased malignancy in MEFs and lung cancer cells (Fig. 4c-e). 
Accordingly, KrasG12D/G12D MEFs showed a highly penetrant colonisation phenotype inducing 
lung tumours in 8/8 recipient mice following intravenous (i.v.) transplantation. In contrast, none 
of the KrasWT/WT (n=5, data not shown) and only 1/8 KrasG12D/WT recipients developed a lung 
lesion. Similarly, KrasG12D/G12D lung cancer cells exhibited a significantly increased metastatic 
potential relative to heterozygous cells, establishing a direct link between Krasmut gains and lung 
cancer malignancy. 
Lastly, we defined the therapeutic impact of glucose metabolism rewiring in vivo by treating early 
and late lung tumours with 2DG+BSO. Similarly to MEFs and lung cancer cells, late tumours 
(where KrasG12D allele prevalence is increased (Fig. 4a)), were significantly more sensitive than 
early tumours to 2DG+BSO treatment (Fig. 4f). Thus, despite the presence of a KrasG12D allele 
(and p53 inactivation) in both groups and their comparable proliferation (Fig. 4f, CTRL), low and 
high-grade lung tumours have distinct and mutant Kras copy number-dependent therapeutic 
susceptibilities. 
Kras allelic imbalance7 and mutant Kras upregulation9 were shown to select for p53 inactivation 
and correlate with tumour progression but the oncogenic effects of enhanced mutant Kras 
signalling remained unclear. Here we show that even in the absence of p53, KrasG12D/WT and 
KrasG12D/G12D cells are phenotypically distinct, with mutant Kras copy gain driving gain-of-
functions that include upregulation and reprogramming of glucose metabolism, enhanced ROS 
management and increased metastatic potential. It is possible that loss of the KrasWT allele 
contributes to the phenotypes observed in KrasG12D/G12D cells24,25. However, since the majority of 
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advanced murine lung tumours retain the wild-type allele (Fig. 4a) we argue that mutant Kras 
gains are the more likely target of positive selection during lung cancer progression. In 
agreement, KRASWT-loss is uncommon while mutant and wild-type KRAS gains are frequent 
features of mutant KRAS human lung adenocarcinoma2,10,26.  
Importantly and consistent with our findings, TCGA copy number variation (CNV) and RNAseq 
data analysis of 65 mutant KRAS lung adenocarcinomas1 revealed that, despite likely allelic 
gain heterogeneity10, combined KRAS mutation and copy gain correlate with glycolysis and 
glutathione metabolism pathway upregulation (KRASmut&CG, Fig. 4g and Extended Data Table 
2). These data confirm that mutant KRAS lung tumours are not a single metabolic entity and 
that, similarly to murine tumours, they may comprise (at least) two disease subgroups with 
distinct genetic and metabolic signatures and unique therapeutic susceptibilities. We argue that 
this heterogeneity may have contributed to the poor treatment responses of KRAS mutant 
tumours and hence, that combined quantitative and qualitative KRAS locus assessment may 
have both prognostic and therapeutic utility. 
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Figure Legends 
Figure 1. Mutant Kras copy gain upregulates glycolysis in MEFs and lung tumour cells. 
a, Proliferative rate of KrasWT/WT (WT/WT), KrasG12D/WT (G12D/WT) and KrasG12D/G12D 
(G12D/G12D);p53Fx/Fx MEFs. b, FACS analysis denoting BrdU+ MEFs. c, MEF Ras levels 
(immunoblotting) and activation (Raf-GST pull-down, normalised to WT/WT). d, Heatmap 
illustrating differential gene expression between G12D/WT and G12D/G12D MEFs 
(n=3/genotype, microarray); top canonical pathways altered shown (IPA). e, Glycolytic gene 
expression (MEF microarray-based heatmap). Genes significantly upregulated in G12D/G12D 
cells highlighted (Bold red, t-test). f, MEF glucose consumption and lactate secretion. g, Left: 
KrasG12D/KrasTotal allelic frequency (pyrosequencing) versus Ras activation or glycolysis (ECAR) 
in KrasG12D/WT;p53-deficient  murine lung tumour cells (n=6) (Pearson’s correlation). Right: 
Glucose consumption and lactate secretion in G12D/WT and G12D/G12D cell line pair (t-test). 
h, Ras activation (normalised to H358), glucose consumption and lactate secretion in KRASmut 
heterozygous (HET: H23, H358) or homozygous (HOM: H460, SW1573) NSCLC cell lines. 
c,f,h, one-way ANOVA. a-c, Representative data of three independent MEFs/genotype; d-f, 
n=3/genotype. g,h, (histograms) Representative data (n=3 independent experiments). All 
graphs depict triplicate mean ±s.d (error bars). ***P<0.001, **P<0.01, *P<0.05. 
 
Figure 2. Mutant Kras copy gain drives glycolysis and directs glucose metabolism 
towards TCA cycle and glutathione synthesis. 
Glucose metabolism flux analysis. a, Carbon flux (grey) from uniformly labelled 13C-glucose 
(13C-GLC) illustrated. Glucose metabolism profiles of indicated MEFs (b), murine (c) and human 
lung cancer cells (d) following LC-MS analysis. b-d, Representative data depict abundance of 
selected labelled metabolites. Triplicates (heatmaps) and triplicate mean ±s.d (graphs) shown. 
MEFs and human cell lines: one-way ANOVA; murine cell lines: t-test. ***P<0.001, *P<0.05. 
 
	  	   13	  
Figure 3. Mutant Kras copy-number dictates redox state, metabolic dependencies and 
therapeutic susceptibilities.  
a, Total and phosphorylated Pdhe1a levels and Pdh activity in MEFs. b, Cellular ROS 
(CellRox); c, NADPH/NADP+ ratio and NADPH levels; d, GSH/GSSG ratio and GSH levels in 
MEFs. e, MEF survival upon 24 hrs H2O2 treatment. f, Nrf2 and Nrf2-target gene expression in 
MEFs (left: qPCR; right: microarray). Nrf2-targets significantly upregulated in homozygous 
MEFs highlighted (bold red, t-test). g, MEF viability after 72 hrs culture in low glucose (Low 
GLC), 2DG or low glutamine (Low GLN), relative to normal media (CTRL). h, Percentage of 
AnnexinV+/PI+ (AnV/PI positive, FACS) MEFs upon 48 hrs BSO, 2DG, or combined (2DG+BSO) 
treatment. i, GSH/GSSG ratio and GSH levels in KRASmut NSCLC cells. j, NSCLC cells treated 
as in (h). Triplicate mean ±s.d. shown for three independent MEFs/genotype (a,c,d,f) or for 
representative data (3 independent runs) (b,e,g,h,i,j). Data normalised to WT/WT (a,c-f) or HET 
mean (i). One-way (a-f,i) or two-way ANOVA (g,h,j). ***P<0.001, **P<0.01, *P<0.05, ns= not 
significant. 
 
Figure 4. Mutant Kras copy gain results in increased malignancy and metabolic rewiring 
in vivo.   
a, Representative H&E sections (scale bar: 20 µm) and KrasG12D allelic frequency 
(pyrosequencing) in independent KrasG12D/+;p53Fx/Fx early and late lung tumours (n=4 
mice/cohort) and normal lung (“Early”, “Late”, “Normal”; respectively). b, Relative abundance of 
selected 13C-glucose-derived metabolites (LC-MS) in samples from (a) (n=3 Normal, n=16 
Early, n=12 Late). c, Representative imaging and luciferase activity/mouse 3 weeks after MEF 
transplantation (n=8/genotype). d, Representative H&E and quantification of lung tumours in 
MEF recipients (t-test). Arrows: lung tumours, scale bars: 2 mm (large), 250 µm (small). e, Left: 
luciferase imaging of lung cancer cell recipients (L1212, L1211), 3 weeks after transplantation 
(n=5/genotype, left). Right: recipient survival (Kaplan-Meier, n=9/genotype). f, Ki67+ 
quantification of Early and Late tumours treated for 48 hrs with 2DG+BSO or vehicle (CTRL) 
(n=3 mice/cohort). g, KRASmut TCGA lung adenocarcinoma1 analysis following tumour 
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segregation into “KRASmut” (mutation) and “KRASmut&CG” (mutation+copy gain) cohorts. KRAS 
copy number/tumour shown (upper left). Differential expression of glycolysis and glutathione 
pathway genes illustrated (RNAseq, IPA; bottom left). Glycolytic genes significantly upregulated 
in KRASmut&CG tumours (bold red, RNAseq) or G12D/G12D MEFs (boxes, microarray) relative to 
heterozygous illustrated (right). Mean ±s.e.m (a,f,) or ±s.d. (d) shown. a,e, One-way Anova. 
***P<0.001, **P<0.01, *P<0.05, ns= not significant. 
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Methods 
Mice, adenoviral infection and treatments 
Animals were maintained under SPF conditions and in compliance with UK Home Office 
regulations. KrasLSL-G12D (6) mice were crossbred to p53Fx (12) to obtain mixed background 
(C57Bl/6/129/Sv) KrasLSL-G12D/+;p53Fx/Fx (for spontaneous tumours and MEF generation) or 
Kras+/+,p53+/+ (transplantation recipients) mice. Endogenous lung tumours were generated 
through intranasal administration of 8-10 week-old KrasLSL-G12D/+;p53Fx/Fx mice (termed 
KrasG12D/WT;p53null) with Cre-expressing adenovirus (5  x  107  plaque-forming units per mouse, 
University of Iowa Vector Core, USA), as previously described7. For therapeutic studies tumour 
bearing mice were treated 12 (early group) or 16 weeks (late group) after Cre administration 
with a combination of 1000 mg/kg 2DG and 10 mmol/kg BSO or vehicle (saline) once a day for 
2 days (i.p.). Lungs were collected 24 hrs after the last treatment and formalin fixed (of note: 
2DG+BSO treatment was sometimes associated with a temporary decrease in motility in both 
control and tumour bearing mice).  
For transplantation studies 8-12 week-old syngeneic wild-type mice were sub-lethally irradiated 
(4Gy, Cesium source) 6 hrs prior to tail vein injection with 1x105 cells in 100 µl PBS. Baseline 
luminescence values were collected 24 hrs after transplantation and tumour growth monitored 
weekly by bioluminescence imaging following i.p. injection with D-luciferin (150 mg/kg) using an 
IVIS Spectrum Xenogen machine (Caliper Life Sciences). Relative luciferase activity 
corresponds to change from baseline at indicated timepoint, normalised to blank control 
(luciferase-negative animal). For tumour load analysis lungs were collected 3 weeks after 
transplantation while tumour survival represents the onset of moderate signs of disease. Two 
independent MEFs per genotype were used in transplantation studies (four recipients/MEF line). 
Lung cancer cell lines (L1211 and L1212) were each transplanted onto five (tumour load study) 
or nine recipient mice (survival). All studies involved animals of both sexes and no animals were 
excluded from the analysis. Cohort sizes were calculated based on published data7 and pilot 
studies and animals randomised based on gender and age. Tumour analysis was carried out 
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blindly. No tumour exceeded the maximum size approved by the animal welfare 
committee/regulations. 
Generation and culture of MEFs and tumour cell lines  
For MEF generation, KrasLSL-G12D/+ ;p53Fx/Fx animals were interbred and embryos collected at day 
E12.5, to overcome KrasLSL-G12D/G12D embryonic lethality27, and Cre-mediated recombination 
performed immediately after MEF generation. In short, cells were cultured in DMEM 
supplemented with 10% FBS, 2 mM L-Glutamine for one passage and then infected with 
adenovirus-Cre (5  ×  107  plaque-forming units/1 x 106 cells). Cre-mediated recombination was 
confirmed by PCR. MEF data were typically obtained using 3 independent MEFs/genotype and 
a minimum of 2 independent MEFs/genotype was used in all cases. All (short-term) assays 
were performed in low-passage MEFs (P1-4 post-Cre). For assessment of proliferative capacity 
MEFs were cultured under standard 3T3 protocol. Briefly, at every passage 3  x 105 cells were 
plated in triplicate on 6 cm plates and counted 3 days later. Cumulative cell number was 
calculated as Log(Nf/Ni)/Log2, where Ni and Nf correspond to number of cells plated and final 
counts/passage, respectively. Murine lung tumour cell lines were generated from independent, 
spontaneous “late” lung tumours from three KrasLSL-G12D/+;p53R270H/ER (6,29) mice. Tumour cells 
were dissociated by collagenase/dispase (Roche) treatment and cultured in DMEM/F12 media 
supplemented with 10% FBS, 2 mM L-Glutamine. Human NSCLC cell lines were recently 
purchased from ATCC (authenticated) and cultured in RPMI media supplemented with 10% 
FBS, 2 mM L-Glutamine.  
AnnexinV/PI FACS analysis was performed as described28. For BrdU/PI FACS cells were 
labelled with 10 mM BrdU (Sigma) for 2 hrs. After harvest, cells were fixed and stained with 
FITC-conjugated Anti-BrdU monoclonal antibody (Becton Dickinson), according to 
manufacturer’s protocol and resuspended in PBS containing 20 µg/ml of propidium iodide (PI). 
FACS was performed using a LSRII (BD, UK) flow cytometer and analysed with FlowJo 
software (Treestar, USA). Cell viability following nutrient deprivation and H2O2 administration 
was determined by trypan blue exclusion (0.4%, Gibco,) or Crystal Violet (0.2%, Sigma), 
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respectively. For in vivo luciferase imaging MEFs and tumour cells were transduced with a 
MSCV-luciferase-hygromycin retrovirus and selected (350µg/ml hygromycin b) prior to i.v. 
transplantation. All cells used in this study tested negative for mycoplasma contamination. In 
vitro assays were carried out in triplicate and run at least three independent times. 
Ras and Pdh expression and activity 
Ras activation was determined by Raf-GST pull-down based ELISA using 100 µg 
protein/sample (whole cell lysates) (Merck Millipore, Ras activation Elisa kit, #17-497). Pdh 
activity was determined with a Pdh	  enzyme activity assay kit (#ab109902, Abcam), according to 
manufacturers instructions. Immunoblotting (40 µg protein/sample) was performed with anti-Ras 
(Cell Signalling, #3339), anti-phospho-Pdhe1a (Ser  293; AP1062; Calbiochem), total Pdhe1a 
(9H9AF5; #459400; Life Technologies)  or anti-β-Tubulin (Cell Signalling #2146, loading control) 
antibodies.  
Gene expression profiling, IPA analysis and qPCR validation. 
Microarray analysis was performed on three independent MEFs/genotype using Illumina 
MouseWG-6 v2.0 Expression BeadChip (Department of Pathology, Cambridge University). 
Normalised Log2 values were determined and average Log Fold Change (LogFC) calculated for 
each comparison. Pathway analysis of genes differentially expressed (>1.3 fold) between 
genotypes was performed using Ingenuity IPA analysis software (ingenuity.com) and statistical 
significance (P<0.05) of canonical pathways determined by Benjamini-Hochberg multiple testing 
correction. Relative gene expression was depicted by heatmaps generated using GENE-E 
software and statistical significance (P<0.05) determined by t-test. Gene expression changes 
were validated by qPCR using ROCHE Universal Probe Library System or Life Technologies 
probes and all data normalised to 18S expression. 
Immunohistochemistry (IHC)  
H&E and Ki67 (Bethyl labs, IHC-00375) IHC was performed on formalin-fixed, 5 µm paraffin-
embedded tissue sections. For transplantation studies the total number of tumours in a single 
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representative H&E section/animal (minimum of 4 lung lobes/section) is shown. For 
endogenous tumours the percentage of proliferating cells was determined as Ki67+/DAPI+ 
nuclei/tumour from a single representative section/animal (minimum of 4 lung lobes/section)). 
All cells or a minimum of 4000 (and >50% coverage) DAPI+ nuclei/tumour were counted from an 
average of 5.25 tumours/mouse. 
Extracellular flux profiling 
OCR and ECAR levels were determined using a Seahorse XFe24 analyser. 2x104 MEFs or 
4x104 tumour cells were plated in Seahorse XFe24 assay plates. Immediately prior to analysis, 
media was replaced by bicarbonate free DMEM Sigma supplemented with 143 mM NaCl, 2% 
FBS, and where appropriate, 25 mM Glucose, 4 mM L-Glutamine, pH 7.4 and cells incubated at 
37° C for 30 min in a CO2 free incubator. Each cycle of measurement involved 3  min mixing, 
3  min waiting and 3  min measuring. After baseline measurements, testing agent prepared in 
assay medium was injected and followed by subsequent measuring cycles. Glycolysis Stress 
Test: measurement 1-3: basal (no glucose), 4-6: glucose (10 mM), 7-9: complex V inhibitor 
oligomycin (1 µM) and 10-12: 2-Deoxyglucose (2DG, 100 mM). Mitochondrial Stress Test: 
measurement 1-3: normal (basal + 25 mM glucose), 4-6: Oligomycin (1 µM) 7-9: carbonyl 
cyanide m-chlorophenylhydrazone (CCCP, 500 nM) and 10-12: Rotenone (1 µM). Protein 
content (BCA assay, Thermo Fisher, UK) at endpoint or cell number was used for data 
normalization. 
Metabolomics analysis 
In vitro sample preparation: 5x105 MEFs or tumour cells were supplemented with media 
containing uniformly labelled 13C- glucose (25 mM) or glutamine (4 mM) for 4 hrs before 
sampling. Metabolites were extracted from media (extracellular) and cell pellet (intracellular) in 
50% MeOH: 30% AcetoNitrile: 20% H2O + 100 ng/mL HEPES buffer (1 ml/106 cells). Samples 
were incubated at 4o C for 15 min at 700 rpm, before centrifugation at 13,000 rpm. Supernatant 
was transferred to vials for mass spectrometry analysis. In vivo sample preparation: 
KrasG12D/WT;p53Fx/Fx were anaesthetized (isofluorane inhalation) and administered a bolus of 0.4 
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mg/g body weight 13C- glucose by tail vein i.v. before continuous infusion of 0.012 mg/g/min at 
150 µl/hrs for 3 hrs. Normal lungs and independent lung tumours were collected and snap 
frozen. Samples were transferred to Precellys24 tubes, metabolite extraction buffer (as above) 
added (250 µl/10 mg), samples homogenized, centrifuged at 13,000 rpm and supernatant used 
for mass spectrometry analysis. Prior to analysis tissues were biopsied for Kras allelic 
assessment (pyrosequencing). LC-MS metabolomics: Sequant Zic-pHilic (150 mm × 2.1 mm i.d. 
5 µm) column and guard column (20 mm × 2.1 mm i.d. 5 µm) from HiChrom, Reading, UK were 
used for LC separation. Mobile phase A: 20 mM ammonium carbonate plus 0.1% ammonia 
hydroxide in water. Mobile phase B: acetonitrile. Flow rate was maintained at 180 µL/minute 
and gradient was as follows: 0-1 min 70% of B, 16 min 38% of B, 16.5 min 70% of B, 25 min 
70% of B. Mass spectrometer (Thermo QExactive Orbitrap) was operated in full MS and polarity 
switching mode. Samples were randomised in order to avoid machine drifts and run in triplicate. 
Spectra were analysed using XCalibur Qual Browser and XCalibur Quan Browser softwares 
(Thermo Scientific) by referencing to an internal library of compounds. Relative metabolite 
abundance was calculated as percentage of total metabolite pool, and depicted graphically or 
as heatmap using GENE-E software. Samples were run and processed blindly. 
Glucose consumption and lactate measurements 
For glucose consumption analysis 1x105 MEF or tumour cells were incubated for 1 hr with 
fluorescent 6-NBDG (N-23106, Life Technologies, UK) and analysed by FACS (% NBDG 
positive cells). Lactate production was assessed 48 hrs after plating using Lactate Reagent 
(Trinity Biotech, Ireland), according to manufacturer’s instructions. Total lactate was normalized 
to cell number. 
TCGA dataset analysis 
Lung adenocarcinoma patient TCGA data1 (no restrictions) was downloaded from c-Bioportal 
and KRAS mutation and copy number assessed. Tumours with a KRAS mutation and KRAS 
GISTIC score of 0+ were taken forward for analysis (n=65). Samples were divided into two 
cohorts based on GISTIC classification: KRASmut (mutation only, GISTIC=0, n=36) or 
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KRASmut&CG (mutation and copy gain, GISTIC=1&2, n=29). KRAS copy number was calculated 
(2CNVx2) from SNP6 data. Pathway analysis was carried out based on RNAseq1 metabolic gene 
expression data (1430 genes) using IPA software, as described above.  
Reagents 
Metabolic probes: 6-NBDG (30 µM), Mitotracker Green (50 nM), TMRM (50 nM), NAO (200 nM) 
and Cell Rox deep red (5 µM) were obtained from Life Technologies (UK). Cellular ROS was 
determined using CellRox deep red probe (Life Technologies, UK, C10422) and FACS analysis. 
GSH/GSSG and NADPH/NADP levels and ratios were calculated according to manufacturers 
instructions (Promega, V6611 and G9081, respectively). Normal and low GLC and GLN (Sigma) 
correspond to 25 mM and 5 mM, and 4 mM and 0.5 mM respectively. Cells were treated with 
the following agents, either alone or in combination as indicated: 100 µM H2O2, 10 mM 2DG and 
2 mM (tumour cells) or 5 mM BSO (MEFs). Total protein content was assessed using 
Sulforhodamine B (Sigma, 0.057% w/v), and total RNA content extracted with TRIzol (Life 
Technologies). NAC (4 mM, Sigma) was added to cells daily. 
Pyrosequencing Analysis 
Genomic DNA (from MEFs, tumour cells and tumours) was isolated and Kras WT/mutant allelic 
ratio determined by pyrosequencing (PyromarkQ24, Qiagen) according to the manufacturer's 
instructions. Pyrograms were analysed (PyroMarkQ24 software) and WT and mutant Kras 
allelic frequency determined based on standards (WT:mutant ratios 2:0, 1:1, 0:2) and shown as 
percentage of total Kras content. 
Primers and probes 
Genotyping: KrasLSL-G12D (6) and p53Fx (12) alleles were genotyped as reported. Microarray 
validation primers and probes: (UPL library, Roche): Gapdh: F 5’ gggttcctataaatacggactgc 3’, R 
5’ ccattttgtctacgggacga 3’, Probe #52; Slc2a1: F 5’ ggatcccagcagcaagaag 3’, R 5’ 
ccagtgttatagccgaactgc 3’, Probe #76; Pfkl: F 5’ gggtcatgtacagcgagga 3’, R 5’ 
ggcctccatacccatcttg 3’, Probe #41; Eno1: F 5’ gaggacactttcatcgcagac 3’, R 5’ 
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ccagctcttcctcaattctga 3’, Probe #77. Nrf2: Mm00477784_m1, Ldha: Mm01612132_m1 (Life 
Technologies), 18S: 4352930E (Thermo Fisher). Pyrosequencing: (Qiagen Q24 
pyrosequencing assay) mKrasG12DF: 5’ gtaaggcctgctgaaaatgactga 3’; mKrasG12DR: 5’ 
[Btn]tatcgtcaaggcgctcttgc 3’, mKrasG12DS (sequencing primer) 5’ tgaaaatgactgagtataaa 3’. 
Statistical Analysis 
Data was visualised and statistical analyses performed using Prism 5.0 software (Graph Pad) or 
R statistical package. P<0.05 was considered statistically significant. In all cases, experimental 
groups showed comparable variance. P values for unpaired comparisons between two groups 
with comparable variance were calculated by two-tailed Student’s t-test. One-way ANOVA (all 
groups against wild-type (WT) group) was used for analysis between three or more groups with 
comparable variance, followed by Bonferroni post-test for individual comparisons. Ordinary two-
way ANOVA (treatment groups against individual genotype control group with comparable 
variance) was used for analysis that involved two variables, followed by Bonferroni post-test for 
individual comparisons. Kaplan Meier comparison was used for analysis of survival cohorts. 
Pearson’s correlation analysis was used to compare relationship between variables in groups 
with similar distribution. TCGA gene expression data was analysed using negative binomial 
generalised linear model (DESeq2). *P<0.05, **P<0.01, ***P<0.001. Error bars indicate mean 
±s.d. or s.e.m., as indicated.  
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Extended Data Figure Legends 
Extended Data Fig. 1. Enhanced glycolysis in homozygous KrasG12D cells. 
a, Representative data (n=3) of PCR analysis of the Kras and p53 loci in KrasWT/WT (WT/WT), 
KrasG12D/WT (G12D/WT) and KrasG12D/G12D (G12D/G12D); p53Fx/Fx MEFs after Cre-mediated 
recombination; and of unrecombined KrasLSL-G12D/WT;p53loxP/loxP control (Cre-) (*: background 
band). b, IPA analysis of canonical pathways significantly altered in KrasG12D/G12D relative to 
KrasG12D/WT MEF transcriptomes (n=3/genotype). c, Representative qPCR data (n=3) of 
glycolytic gene expression in MEFs. Fold change relative to WT/WT shown as triplicate mean 
±s.d. (one-way ANOVA). d, Extracellular acidification rate (ECAR) in MEFs following exposure 
to glucose, oligomycin and 2DG. Representative data from three independent MEFs/genotype 
show mean value between triplicates ±s.d. (two-way ANOVA). e, Kras locus analysis of two 
lung cancer cell lines (L1212 and L1211) generated from spontaneous tumours from 
KrasG12D/WT;p53-deficient mice. PCR (top) and pyrosequencing (lower panel) analysis shown 
(L1212: Kras heterozygous - G12D/WT; L1211: G12D homozygous - G12D/G12D). 
Recombined heterozygous MEFs shown as PCR control (CTRL). f, Representative qPCR data 
(n=3) of glycolytic gene expression in L1211 and L1212 lung tumour cells. Fold change relative 
to heterozygous cells shown (mean of triplicates ±s.d., ***P=<0.001, *P<0.05, t-test). g, Left: 
basal glucose consumption in murine lung tumour cells determined by FACS analysis of 6-
NBDG uptake (%). *P=0.02, t-test. Right: extracellular lactate concentration (ng/dl/cell) in 
murine lung tumour cells. Data are triplicate mean ±s.d. *P=0.0139, t-test.  
 
Extended Data Fig. 2. KrasG12D/WT and KrasG12D/G12D MEFs have similar biomass and 
mitochondrial functionality. 
a, Total protein content in indicated MEFs relative to WT/WT. b, Total RNA per cell for each of 
the indicated genotypes. c, d, WT/WT, G12D/WT and G12D/G12D MEFs were profiled by 
CASY counter (Roche) and cell volume (c) and diameter (d) measured. a-d, Mean value of 
three independent MEF triplicates/genotype ±s.d. shown. e, Oxygen consumption rate (OCR) of 
MEFs in response to oligomycin, CCCP and rotenone (two-way ANOVA). f, NAO staining was 
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used to determine mitochondrial mass in KrasWT/WT (WT/WT), KrasG12D/WT (G12D/WT) and 
KrasG12D/G12D (G12D/G12D) MEFs. Geometric mean of NAO fluorescence in cells was 
determined by FACS. Representative overlay (left panel) and geometric mean (right panel) 
displayed. g, Mitochondrial architecture was examined after Mitotracker green staining in 
WT/WT, G12D/WT and G12D/G12D MEFs (scale= 10µm). h, TMRM staining was used to 
determine mitochondrial membrane potential in MEFs of indicated genotypes. Geometric mean 
of TMRM fluorescence in cells was determined by FACS. Representative overlay (left panel) 
and geometric mean (right panel) displayed. e-h, Representative data of 3 independent 
MEFs/genotype show mean of triplicates ±s.d., ***P<0.001, one-way ANOVA.  
 
Extended Data Fig. 3. Glucose metabolism reprogramming in KrasG12D/G12D MEFs. 
a-j, Measurement of 13C-glucose-derived metabolites, calculated as a percentage (%) of the 
total metabolite pool following LC-MS analysis of WT/WT, G12D/WT and G12D/G12D MEFs 
after 4 hrs culture with 13C-glucose supplemented media. Representative data (of 2 independent 
MEFs/genotype) showing mean of triplicates ±s.d., ***P<0.001, **P<0.01, *P<0.05 (two-way 
ANOVA). Undetected isotopologues not shown. 
 
Extended Data Fig. 4. Glucose metabolism reprogramming in lung tumour cells with 
mutant Kras copy gain. 
Measurement of 13C-glucose-derived metabolites, calculated as a percentage (%) of the total 
metabolite pool following LC-MS analysis of murine (L1211 and L1212, a-h) and human (H23, 
H358, H460, SW1573, i-p) mutant Kras heterozygous and homozygous lung tumour cells. Cells 
were cultured for 4 hrs with 13C-glucose supplemented media prior to analysis. Data show mean 
of triplicates ±s.d., ***P<0.001, **P<0.01, *P<0.05 (two-way ANOVA, relative to Krasmut 
heterozygous cells; i-p, homozygous samples significantly different from both heterozygous cell 
lines indicated). Undetected isotopologues not shown. 
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Extended Data Fig. 5. KrasG12D/WT and KrasG12D/G12D MEFs have distinct glutamine 
metabolism profiles. 
Glutamine metabolism analysis in WT/WT, G12D/WT and G12D/G12D MEFs. a, 
Representation of carbon flux (grey circles) from uniformly labelled 13C-labelled glutamine (13C-
GLN). b, Heatmap illustrates abundance of selected labelled metabolites across triplicates of 
representative MEFs (two independent MEFs/genotype analysed) based on metabolomics 
analysis. c-i, Measurement of 13C-glutamine-derived metabolites, calculated as a percentage of 
the total metabolite pool following LC-MS analysis of WT/WT, G12D/WT and G12D/G12D MEFs 
after 4 hrs culture with 13C-glutamine supplemented media. Representative data (2 independent 
MEFs/genotype) show mean of triplicates ±s.d., (two-way ANOVA). j, Oxygen consumption rate 
(OCR) of WT/WT, G12D/WT and G12D/G12D MEFs upon glutamine (4 mM) addition. 
Representative data of 3 independent MEFs/genotype showing mean of triplicates ±s.d. k, 
Relative diversion (%) of glutamine to TCA (aKG m+5) or GSH (GSH m+5) in MEFs of indicated 
genotypes based on metabolomics data. Representative MEF data (n=2 MEFs/genotype) 
shows triplicate mean ±s.d. (one-way ANOVA). ***P<0.001, **P<0.01, *P<0.05. 
 
Extended Data Fig. 6. KrasG12D homozygous cells depend on glucose metabolism 
reprogramming for ROS management. 
a, GSSG levels in G12D/WT and G12D/G12D MEFs relative to WT/WT. Mean data (n=3 
MEFs/genotype) ±s.d. shown. b, ROS levels in MEFs following 48 hrs of 2DG treatment. Data 
were normalised to vehicle treatment (CTRL). c, Percentage of AnnexinV/PI (AnV/PI) double 
positive G12D/G12D MEFs following 48 hrs of 2DG treatment in the presence (+) or absence (-) 
of NAC. d, Ratio of reduced to oxidised glutathione (GSH/GSSG) determined for WT/WT, 
G12D/WT and G12D/G12D MEFs after incubation with 2DG, BSO or both (2DG+BSO) for 48 
hrs, normalised to vehicle (CTRL). b-d, Representative data from 3 independent 
MEFs/genotype presented. Mean data for triplicates ±s.d. shown (two-way ANOVA). e, 
Representative data of GSH/GSSG ratio and GSH levels in murine G12D/G12D tumour cells 
relative to G12D/WT (t-test). f, Differential sensitivity of lung tumour cells to nutrient depletion. 
	  	   25	  
Lung tumour cells were cultured in normal media (CTRL) and low glucose (Low GLC) conditions 
for 72 hrs and viable cells counted and normalised to CTRL (two-way ANOVA). g, Percentage 
of AnnexinV/PI double positive murine tumour cells following 48 hrs treatment with BSO, 2DG, 
or both (2DG+BSO). e-g, Representative data (n=3 independent experiments) depicts triplicate 
mean ±s.d. (***P<0.001, two-way ANOVA). ***P<0.001, **P<0.01, *P<0.05. 
 
Extended Data Fig. 7. Increased mutant Kras allelic content leads to glucose metabolism 
reprogramming in lung tumours in vivo. 
a-i, Control (no Cre) and tumour bearing KrasG12D/+;p53Fx/Fx mice were infused with 13C-glucose 
12 (early group) or 16 weeks (late group) after adenoviral-Cre treatment and individual lung 
tumours (Early, n=16 and Late, n=12) or control lung (Normal, n=3) collected for LC-MS 
analysis (3 technical replicates/sample). Selected 13C-glucose-derived metabolites shown, 
calculated as a percentage of the total metabolite pool. Mean abundance per cohort ±s.e.m. 
shown.  ***P<0.001, *P<0.05 (two-way ANOVA). 
 
Extended Data Table 1. Mutant heterozygous and homozygous KRAS NSCLC cell lines. 
KRAS mutation and zygosity of 4 NSCLC cell lines according to COSMIC Cell Lines project 
database (version 73). Genotypes were confirmed by Sanger Sequencing (data not shown). 
 
Extended Data Table 2. KRAS status in panel of human lung adenocarcinomas. 
KRAS mutation, GISTIC score and copy number variation (CNV) in TCGA lung 
adenocarcinoma dataset1. KRAS mutation (status and nucleotide substitution), KRAS putative 
copy number calls from GISTIC 2.0 analysis (GISTIC score) and KRAS Log2 copy number 
values (from Affymetrix SNP6) were downloaded from cBioportal. Mutant KRAS tumours with a 
GISTIC score of 0+ (n=65) were divided into two cohorts: KRAS mutant (KRASmut, GISTIC= 0, 
n=36) and KRAS mutant & copy gain (KRASmut&CG, GISTIC= 1&2, n=29), as displayed. 
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Extended Data Table 1
Cell line KRAS Mutation Cell line KRAS Mutation
NCI-H23 p.G12C NCI-H460 p.Q61H
NCI-H358 p.G12C SW1573 p.G12C
KRAS Heterozygous KRAS Homozygous
Extended Data Table 2
ID KRAS
mutation 
KRAS
GISTIC 
ID
TCGA-78-7539-01 G12C 0 -0.065 TCGA-95-7567-01 G12V 1 0.135
TCGA-78-7160-01 G12D 0 -0.032 TCGA-78-7148-01 G12C 1 0.255
TCGA-49-6761-01 G12D 0 -0.032 TCGA-55-7726-01 G12C 1 0.34
TCGA-50-5933-01 G12C 0 -0.027 TCGA-55-7911-01 G12V,K88* 1 0.358
TCGA-05-4403-01 G12C 0 -0.008 TCGA-05-4415-01 G12C 1 0.38
TCGA-35-3615-01 G12C 0 -0.008 TCGA-75-5126-01 G12C 1 0.399
TCGA-55-6970-01 G12V 0 -0.008 TCGA-05-4390-01 G12V 1 0.4
TCGA-75-7030-01 G12D 0 -0.005 TCGA-05-4418-01 G12C 1 0.404
TCGA-55-6983-01 G12C 0 0 TCGA-73-4662-01 G12C 1 0.411
TCGA-55-7725-01 G12V 0 0 TCGA-49-4510-01 G12D 1 0.413
TCGA-44-6146-01 G12V 0 0 TCGA-78-7161-01 G12V 1 0.481
TCGA-78-7540-01 G12V 0 0.001 TCGA-78-7145-01 G12Y 1 0.523
TCGA-67-3773-01 G12V 0 0.002 TCGA-86-7713-01 G12C 1 0.547
TCGA-97-7941-01 G12A 0 0.004 TCGA-05-4417-01 G12C 1 0.585
TCGA-49-4505-01 G12C 0 0.004 TCGA-91-6828-01 G12V 1 0.632
TCGA-78-7166-01 G12C 0 0.004 TCGA-69-7980-01 G12A 1 0.647
TCGA-44-7659-01 G12C 0 0.004 TCGA-55-7907-01 G12C 1 0.746
TCGA-44-6776-01 G12D 0 0.004 TCGA-55-7728-01 G12V 1 0.797
TCGA-50-7109-01 G12C 0 0.005 TCGA-75-7027-01 G12V 1 0.812
TCGA-50-5932-01 G12C 0 0.011 TCGA-50-5941-01 G12A 1 1.458
TCGA-55-7281-01 G12C 0 0.012 TCGA-64-5775-01 Q61L 1 1.752
TCGA-80-5608-01 G12A 0 0.019 TCGA-05-4395-01 G12V 1 2.25
TCGA-05-4249-01 G12C 0 0.024 TCGA-55-7815-01 G12V 2 0.491
TCGA-53-7813-01 G12A 0 0.032 TCGA-55-7283-01 G12S 2 0.64
TCGA-64-5774-01 G12C 0 0.034 TCGA-97-7554-01 G12V 2 0.836
TCGA-93-7347-01 G12C 0 0.036 TCGA-55-7576-01 G12S 2 0.875
TCGA-38-4626-01 G12V 0 0.044 TCGA-05-4433-01 G12V 2 1.082
TCGA-44-6777-01 G12C 0 0.045 TCGA-67-3774-01 G12F 2 1.095
TCGA-64-1677-01 G12C 0 0.051 TCGA-44-7672-01 G12A 2 2.604
TCGA-05-4430-01 G12C 0 0.056
TCGA-49-6744-01 G12C 0 0.058
TCGA-73-4659-01 G12V 0 0.069
TCGA-50-5936-01 G12C 0 0.088
TCGA-78-7167-01 G12F 0 0.093
TCGA-55-6642-01 G12V 0 0.099
TCGA-44-6145-01 G12V 0 0.099
KRASmut KRASmut&CG
KRAS
CNV 
KRAS
mutation 
KRAS
GISTIC 
KRAS
CNV 
